Thrombolytic Therapy for Non-arteritic Central Retinal Artery Occlusion in an Academic Multi-site Stroke Center (S45.010)

作者
Nour Alhayek,Jacob M. Sobczak,Emilie Weinberg,Bart M. Demaerschalk,Oana Dumitrașcu
出处
期刊:Neurology [Lippincott Williams & Wilkins]
卷期号:100 (17_supplement_2) 被引量:3
标识
DOI:10.1212/wnl.0000000000203399
摘要

Objective: To review our academic multi-site stroke center experience with intravenous (IVT) and intra-arterial thrombolysis (IAT) for central retinal artery occlusion (CRAO). Background: CRAO is a subtype of acute ischemic stroke leading to severe visual loss. Conventional management is not effective and potentially harmful. 2021 American Heart Association scientific statement proposes similar time-windows for thrombolysis in CRAO and cerebral strokes (4.5hours for IVT, 6hours for IAT). Design/Methods: We retrospectively identified consecutive CRAO patients that received IVT or IAT in our academic enterprise stroke centers (1997–2022). Demographic, clinical characteristics, thrombolysis timeline, concurrent CRAO therapies, hospital complications, and follow-up visual outcomes were collected and analyzed using descriptive statistics. Results: Of 563 CRAO admissions, 20 (3.55%) received thrombolytic therapy: 13 IVT (mean age 68, range 55–82, 61.5% male, 12 alteplase and 1 tenecteplase, all embolic etiology) and 7 IAT (mean age 55, range 17–83, 85.7% male, 4 post-operative and 3 embolic). 11/20 (55%) received additional therapies (ocular massage, intraocular pressure lowering drops, diuretics, intra-arterial verapamil). 1 CRAO mimic received IVT. Median visual loss to IVT was 158 minutes (range 67–260 min). Baseline mean logMAR visual acuity (VA) was −3.11 (±1.16). 8/13 IVT had 3-month follow-up VA recorded (mean VA −2.53). 50% improved at least one Snellen line, 12.5% had VA > 20/100. 1/13 (7.6%) had intracranial hemorrhage after IVT. Median visual loss to IAT was 335 minutes (131 minutes to 20 hours). Dose range was 5–30 mg. Baseline IAT mean logMAR VA was −3.5 (±1.19). 5/7 showed VA improvement. 1/7 had profuse epistaxis after IAT. Conclusions: The management of acute CRAO in a multi-site academic stroke center remains heterogeneous, consultant specific. Most received a combination of thrombolytic and other conventional therapies, hence thrombolysis-specific outcomes could not be described. Prospective studies comparing thrombolysis and placebo are warranted to guide hyperacute CRAO practice. Disclosure: Dr. Alhayek has nothing to disclose. Mr. Sobczak has nothing to disclose. Miss Weinberg has nothing to disclose. Dr. Demaerschalk has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for The Neurologist . Dr. Dumitrascu has nothing to disclose.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zf完成签到,获得积分10
1秒前
法官大人完成签到,获得积分10
2秒前
dan完成签到,获得积分10
3秒前
孤独的大亩灵完成签到,获得积分10
3秒前
QKD关闭了QKD的文献求助
3秒前
captainHc发布了新的文献求助10
3秒前
yy发布了新的文献求助10
4秒前
内向白开水完成签到,获得积分10
4秒前
mate发布了新的文献求助10
5秒前
dan发布了新的文献求助10
6秒前
Arina完成签到,获得积分20
7秒前
7秒前
天天快乐的应助被红莲墨生采纳,获得10
8秒前
领导范儿的应助被内向白开水采纳,获得10
9秒前
9秒前
许彦晋发布了新的文献求助10
9秒前
11秒前
哈哈发布了新的文献求助10
11秒前
英俊的铭的应助被111采纳,获得10
12秒前
今后的应助被wush采纳,获得10
14秒前
xushijing发布了新的文献求助30
14秒前
14秒前
15秒前
wu发布了新的文献求助10
15秒前
15秒前
0514gr完成签到,获得积分10
15秒前
wu发布了新的文献求助10
16秒前
16秒前
脑洞疼的应助被Lu采纳,获得10
16秒前
要顺利毕业完成签到,获得积分10
16秒前
17秒前
言言柒完成签到 ,获得积分10
17秒前
无花果的应助被坚强孤容采纳,获得10
18秒前
完美世界的应助被nuoyefenfei采纳,获得10
19秒前
wu发布了新的文献求助10
19秒前
19秒前
fanf完成签到,获得积分10
20秒前
乾y完成签到 ,获得积分10
20秒前
20秒前
王贤贤发布了新的文献求助10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184240
求助须知:如何正确求助?哪些是违规求助? 9573297
关于积分的说明 21830585
捐赠科研通 7781300
什么是DOI,文献DOI怎么找? 3434285
关于科研通互助平台的介绍 2558389
邀请新用户注册赠送积分活动 2480814